Regulatory Affairs
NAFDAC Updates Ceiling List, Restricts New Registration of 36 Imported Pharmaceutical Product Categories
NAFDAC has updated its Ceiling List, stopping new registration applications for imported pharmaceutical products covered by the policy. Existing registrations will follow the 5+5 renewal pathway, which requires applicants to submit plans for transitioning to local manufacturing.
The National Agency for Food and Drug Administration and Control (NAFDAC) has updated its Ceiling List, announcing that it will no longer accept new applications for the registration of imported pharmaceutical products covered by the list.
The announcement, published on 28 October 2026, also states that renewal applications for affected products will be processed under the agency's 5+5 policy pathway, which requires applicants to submit a blueprint or plan for transitioning the products to local manufacturing.
The updated list, published alongside the notice, contains 36 product categories covering various medicines and pharmaceutical preparations.
Which pharmaceutical products are affected?
The updated Ceiling List covers several commonly used medicines and pharmaceutical products across different therapeutic categories.
They include:
• Antibiotics: Ampicillin, amoxicillin, amoxicillin/clavulanic acid, erythromycin, tetracycline, ciprofloxacin and ampicillin/cloxacillin.
• Antimalarials: Sulphadoxine/pyrimethamine and piperaquine.
• Anthelmintics: Albendazole and mebendazole.
• Cardiovascular medicines: Amlodipine.
• Analgesics and anti-inflammatory medicines: Ibuprofen, indomethacin and piroxicam.
• Other medicines: Paracetamol-containing fixed-dose combinations, metformin, omeprazole, diazepam, prednisolone, chlorpheniramine maleate, cyproheptadine and griseofulvin.
• Other pharmaceutical preparations: Alcohol-based hand sanitisers, topical benzyl benzoate preparations, topical sulphur ointments, topical penicillin ointments and topical products containing salicylic acid.
The list specifies applicable dosage forms and, in several cases, covers all strengths and dosage forms. Some entries have specific exclusions, including certain parenteral formulations and salbutamol inhalers.
What happens to existing imported products?
NAFDAC's announcement distinguishes between new registration applications and applications for renewal.
Under the updated directive, new applications for the registration of imported pharmaceutical products on the Ceiling List will no longer be accepted.
However, the agency has provided a renewal pathway under its 5+5 policy. Applicants seeking renewal will be required to submit a blueprint or plan demonstrating how they intend to transition the affected product to local manufacturing.
The requirement is intended to move pharmaceutical products that can be manufactured domestically away from dependence on imported finished products.
Why NAFDAC is promoting local pharmaceutical manufacturing
The Ceiling List forms part of NAFDAC's broader regulatory strategy to strengthen domestic pharmaceutical production.
According to the agency's explanation of its local manufacturing policies, the Ceiling List was introduced to prevent the importation of pharmaceutical products that domestic manufacturers have the capacity to produce.
The policy is intended to encourage investment in local manufacturing, improve the availability and affordability of medicines, strengthen the pharmaceutical industry and reduce dependence on imported products.
NAFDAC introduced its 5+5 regulatory directive in 2019 and subsequently expanded the Ceiling List as part of these efforts.
In a separate explanation of the policy published in 2026, the agency reported that more than 70 per cent of products under the 5+5 policy were being manufactured locally. It also outlined the objective of increasing the proportion of locally manufactured medicines in Nigeria.
Implications for pharmaceutical companies and medicine supply
The updated directive has important implications for pharmaceutical importers, marketing authorisation holders and local manufacturers.
Importers and companies holding registrations for affected products will need to consider the local manufacturing transition requirements when preparing for renewal.
For local pharmaceutical manufacturers, the development reinforces the regulatory direction towards domestic production of medicines that can be manufactured within the country.
However, the implementation of this policy will also require attention to manufacturing capacity, product quality, availability of active pharmaceutical ingredients, production costs and the ability of local manufacturers to meet national demand.
For pharmacists and other healthcare professionals, the development is relevant because changes in the pharmaceutical manufacturing and registration landscape can have implications for medicine sourcing and supply.
The transition must therefore be accompanied by sustained attention to quality, safety, efficacy, affordability and continuity of supply.
Strengthening Nigeria's pharmaceutical manufacturing capacity
NAFDAC's updated Ceiling List represents another regulatory step towards promoting local pharmaceutical manufacturing and reducing reliance on imported products.
The effectiveness of the policy will depend not only on restricting new registrations of imported products but also on the capacity of domestic manufacturers to produce quality-assured medicines consistently and at competitive prices.
As implementation progresses, the balance between supporting local industry and maintaining reliable access to essential medicines will remain important to Nigeria's pharmaceutical sector.
More like this
NAFDAC Debunks Claims That Camosunate Has Been Banned in Nigeria
21 Nov 2026
NAFDAC Destroys ₦100 Billion Worth of Falsified, Expired and Banned Products in Ogun State
21 Nov 2026
PCN Seals 261 Medicine Outlets Following FCT Enforcement Exercise
20 Nov 2026